Literature DB >> 23299280

Frequency of epidermal growth factor receptor mutations in Bangladeshi patients with adenocarcinoma of the lung.

Shakibur Rahman1, Nobuyuki Kondo, Kazue Yoneda, Teruhisa Takuwa, Masaki Hashimoto, Hayato Orui, Yoshitomo Okumura, Fumihiro Tanaka, Kanako Kumamoto, Mohammad Golam Mostafa, Golam Mohiuddin Akbar Chowdhury, Akramul Haque, Seiki Hasegawa.   

Abstract

BACKGROUND: Worldwide studies on lung adenocarcinoma have demonstrated a genetic divergence of the epidermal growth factor receptor (EGFR) pathway according to ethnicity, such as higher frequency of activated EGFR mutations among East Asian patients. However, such information is still lacking in some developing countries.
METHODS: We investigated the frequency of EGFR mutations among Bangladeshi patients with adenocarcinoma of the lung. Fine-needle aspiration tissue samples were collected from 61 Bangladeshi patients. Polymerase chain reaction-single-strand conformation polymorphism was performed on extracted DNA for mutational analysis of EGFR exons 19 and 21.
RESULTS: EGFR mutations were found in 14 of 61 (23.0 %) Bangladeshi patients. There was no significant difference in EGFR mutation rate with regard to patient's age, sex, smoking history, clinical stage of lung cancer, subtypes of adenocarcinoma, and tumor differentiation.
CONCLUSION: The present study revealed that the EGFR mutation rate in Bangladeshi patients with adenocarcinoma of the lung was higher than in African-American, Arabian, and white Caucasian patients, and was lower than in East Asia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23299280     DOI: 10.1007/s10147-012-0515-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  16 in total

1.  Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Authors:  Daphne W Bell; Thomas J Lynch; Sara M Haserlat; Patricia L Harris; Ross A Okimoto; Brian W Brannigan; Dennis C Sgroi; Beth Muir; Markus J Riemenschneider; Renee Bailey Iacona; Annetta D Krebs; David H Johnson; Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Masahiro Fukuoka; Mark G Kris; José Baselga; Judith S Ochs; Daniel A Haber
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

Review 2.  Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Emiliano Calvo; José Baselga
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

3.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Authors:  David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

4.  Screening for EGFR mutations in lung cancer, a report from India.

Authors:  Rashmita Sahoo; V Vidya Harini; V Chitti Babu; Geeta V Patil Okaly; Smitha Rao; Ashwini Nargund; E Venkataswamy; Raghavendra Rao; B S Ajai Kumar
Journal:  Lung Cancer       Date:  2011-02-18       Impact factor: 5.705

5.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.

Authors:  Antonio Marchetti; Carla Martella; Lara Felicioni; Fabio Barassi; Simona Salvatore; Antonio Chella; Pier P Camplese; Teodorico Iarussi; Felice Mucilli; Andrea Mezzetti; Franco Cuccurullo; Rocco Sacco; Fiamma Buttitta
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

6.  High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.

Authors:  Shiu-Feng Huang; Hui-Ping Liu; Ling-Hui Li; Yuan-Chieh Ku; Yu-Ning Fu; Hsien-Yu Tsai; Ya-Ting Chen; Yung-Feng Lin; Wen-Cheng Chang; Han-Pin Kuo; Yi-Cheng Wu; Yi-Rong Chen; Shih-Feng Tsai
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

7.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

8.  Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.

Authors:  Rom S Leidner; Pingfu Fu; Bradley Clifford; Ayad Hamdan; Cheng Jin; Rosana Eisenberg; Titus J Boggon; Margaret Skokan; Wilbur A Franklin; Federico Cappuzzo; Fred R Hirsch; Marileila Varella-Garcia; Balazs Halmos
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

9.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

10.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

View more
  4 in total

1.  Targeted Therapy Management in NSCLC Patients Using Cytology: Experience from a Tertiary Care Cancer Center.

Authors:  Vidya H Veldore; Shekar Patil; Shilpa Prabhudesai; C T Satheesh; H P Shashidhara; Naveen Krishnamoorthy; D Hazarika; R Tejaswi; Ankita Prabhudev; Radheshyam Naik; Raghavendra M Rao; B S Ajai Kumar
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

2.  EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

Authors:  Anita Midha; Simon Dearden; Rose McCormack
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

Review 3.  A review on the genetic polymorphisms and susceptibility of cancer patients in Bangladesh.

Authors:  Golap Babu; Shad Bin Islam; Md Asaduzzaman Khan
Journal:  Mol Biol Rep       Date:  2022-03-11       Impact factor: 2.742

4.  Epidermal Growth Factor Receptor Mutation Frequency in Squamous Cell Carcinoma and Its Diagnostic Performance in Cytological Samples: A Molecular and Immunohistochemical Study.

Authors:  Niraj Kumari; Shalini Singh; Dhanjit Haloi; Shravan Kumar Mishra; Narendra Krishnani; Alok Nath; Zafar Neyaz
Journal:  World J Oncol       Date:  2019-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.